TYP 0.00% 2.0¢ tryptamine therapeutics limited

Competition is high, and a few stemcell companies have pivoted...

  1. 259 Posts.
    lightbulb Created with Sketch. 19
    Competition is high, and a few stemcell companies have pivoted into exosomes.

    What makes EX1 different though is that they are creating the pickaxes of actually creating the exosomes. Others will be the miners and make them into useful biologics. EX1 is helping to do that with their studies, but I think it is a play to make the space bigger for them supplying everyone with the exosomes.
 
watchlist Created with Sketch. Add TYP (ASX) to my watchlist
(20min delay)
Last
2.0¢
Change
0.000(0.00%)
Mkt cap ! $21.78M
Open High Low Value Volume
2.0¢ 2.0¢ 2.0¢ $41.51K 2.075M

Buyers (Bids)

No. Vol. Price($)
4 653650 1.9¢
 

Sellers (Offers)

Price($) Vol. No.
2.0¢ 660963 1
View Market Depth
Last trade - 10.08am 29/07/2024 (20 minute delay) ?
TYP (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.